DiosCURE Therapeutics SE, a novel biopharmaceutical company developing next-generation immunotherapeutics against SARS-CoV-2, today announced that it has closed a EUR 2.6 million seed-financing round from venture capital firms and angel investors.
DiosCURE will use the funds to initiate development of its next-generation immunotherapies to prevent and treat SARS-CoV-2. The company's two lead drug candidates DIOS-202 and DIOS-203 are single-chain antibodies that uniquely bind to different surface structures of the viral spike protein. This passive immunization approach will block the virus’ penetration into target cells which inhibits viral spreading and thereby allows the prevention and treatment of SARS-CoV-2 infections.
"Our investors were attracted to our novel immunotherapies that can be highly efficacious, well-tolerated and suppress mutational escape by the virus," said Klaus Wilgenbus, CEO of DiosCURE. "The COVID-19 pandemic is regarded as the biggest global health-care crisis since World War-II. We believe our technology has the potential to make a significant impact in order to overcome this crisis and we will apply all our resources to rapidly advance our lead candidates through development."
The new shareholders of DiosCURE have already indicated that they will provide further funding to move into clinical testing next year.
DiosCURE is developing next-generation immunotherapies focused on a novel approach against SARS-CoV-2. The Company’s proprietary bi- and trivalent variable domains of heavy chain-only antibodies (VHHs) are synergistic combinations of single-domain antibodies, constructed following structural information and optimized for potency as well as their potential to avoid the emergence of escape mutants. DiosCURE designed lead candidates that target two different epitopes of the SARS-CoV-2 spike protein with the potential to be highly efficacious, well-tolerated and manufactured at a large-scale standardized process. To learn more about our company, please visit www.dioscure.com
Klaus Wilgenbus, M.D.
Chief Executive Officer
Eva Mulder or Sophia Hergenhan, Ph.D.
+49 89 238 877 30